Rising prevalence of multiple sclerosis in Saudi Arabia, a descriptive study
Background In 2015, the first nationwide, multicenter Multiple Sclerosis (MS) registry was initiated in the Kingdom of Saudi Arabia (KSA) mainly with an objective to describe current epidemiology, disease patterns, and clinical characteristics of MS in Saudi Arabia. This article aimed to report init...
Saved in:
| Published in: | BMC neurology Vol. 20; no. 1; pp. 49 - 7 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
BioMed Central
08.02.2020
BioMed Central Ltd Springer Nature B.V BMC |
| Subjects: | |
| ISSN: | 1471-2377, 1471-2377 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Background
In 2015, the first nationwide, multicenter Multiple Sclerosis (MS) registry was initiated in the Kingdom of Saudi Arabia (KSA) mainly with an objective to describe current epidemiology, disease patterns, and clinical characteristics of MS in Saudi Arabia. This article aimed to report initial findings of the registry and regional prevalence of MS.
Method
In 2015, a national MS registry was launched in KSA to register all MS patient with confirmed diagnosis according to the 2010 McDonald Criteria. The registry aimed to identify and recruit all healthcare facilities treating MS patients in the Kingdom, and collect data such as demographics, clinical characteristics (disease onset, diagnosis, presentation of symptoms at onset, disease course, relapse rate, and disability measures), family history, and treatments. All the included sites have obtained IRB/EC approvals for participating in the registry. Currently, the registry includes 20 hospitals from different regions across the Kingdom. The Projected prevalence was calculated based on the assumption that the number of diagnosed MS cases in participating hospitals (in each region) is similar to the number of cases in remaining nonparticipant hospitals in the same region.
Results
As of September 2018, the registry has included 20 hospitals from the different regions across the Kingdom and has collected comprehensive data on 2516 patients from those hospitals, with median age 32 (Range: 11–63) and 66.5% being females. The reported prevalence of MS for those hospitals was estimated to be 7.70/100,000 population and 11.80/100,000 Saudi nationals. Based on the assumption made earlier, we projected the prevalence for each region and for the country as a whole. The overall prevalence of MS at the country level was reported to be 40.40/100,000 total population and 61.95/100,000 Saudi nationals. Around 3 out of every 4 patients (77.5%) were 40 years of age or younger. Female to male ratio was 2:1. The prevalence was higher among females, young and educated individuals across all five regions of Saudi Arabia.
Conclusion
The prevalence of MS has significantly increased in Saudi Arabia but is still much lower than that in the western and other neighboring countries like Kuwait, Qatar, and the UAE. However, compared to the past rates, Saudi Arabia’s projected prevalence of MS through this national study is 40.40/100,000 population, putting the Kingdom above the low risk zone as per Kurtzke classification. The projected prevalence was estimated to be much higher among Saudi nationals (61.95/100,000 Saudi-nationals). The prevalence was higher among female, younger and educated individuals. Further studies are needed to assess the risk factors associated with increased prevalence in Saudi Arabia. |
|---|---|
| AbstractList | Background In 2015, the first nationwide, multicenter Multiple Sclerosis (MS) registry was initiated in the Kingdom of Saudi Arabia (KSA) mainly with an objective to describe current epidemiology, disease patterns, and clinical characteristics of MS in Saudi Arabia. This article aimed to report initial findings of the registry and regional prevalence of MS. Method In 2015, a national MS registry was launched in KSA to register all MS patient with confirmed diagnosis according to the 2010 McDonald Criteria. The registry aimed to identify and recruit all healthcare facilities treating MS patients in the Kingdom, and collect data such as demographics, clinical characteristics (disease onset, diagnosis, presentation of symptoms at onset, disease course, relapse rate, and disability measures), family history, and treatments. All the included sites have obtained IRB/EC approvals for participating in the registry. Currently, the registry includes 20 hospitals from different regions across the Kingdom. The Projected prevalence was calculated based on the assumption that the number of diagnosed MS cases in participating hospitals (in each region) is similar to the number of cases in remaining nonparticipant hospitals in the same region. Results As of September 2018, the registry has included 20 hospitals from the different regions across the Kingdom and has collected comprehensive data on 2516 patients from those hospitals, with median age 32 (Range: 11–63) and 66.5% being females. The reported prevalence of MS for those hospitals was estimated to be 7.70/100,000 population and 11.80/100,000 Saudi nationals. Based on the assumption made earlier, we projected the prevalence for each region and for the country as a whole. The overall prevalence of MS at the country level was reported to be 40.40/100,000 total population and 61.95/100,000 Saudi nationals. Around 3 out of every 4 patients (77.5%) were 40 years of age or younger. Female to male ratio was 2:1. The prevalence was higher among females, young and educated individuals across all five regions of Saudi Arabia. Conclusion The prevalence of MS has significantly increased in Saudi Arabia but is still much lower than that in the western and other neighboring countries like Kuwait, Qatar, and the UAE. However, compared to the past rates, Saudi Arabia’s projected prevalence of MS through this national study is 40.40/100,000 population, putting the Kingdom above the low risk zone as per Kurtzke classification. The projected prevalence was estimated to be much higher among Saudi nationals (61.95/100,000 Saudi-nationals). The prevalence was higher among female, younger and educated individuals. Further studies are needed to assess the risk factors associated with increased prevalence in Saudi Arabia. Background In 2015, the first nationwide, multicenter Multiple Sclerosis (MS) registry was initiated in the Kingdom of Saudi Arabia (KSA) mainly with an objective to describe current epidemiology, disease patterns, and clinical characteristics of MS in Saudi Arabia. This article aimed to report initial findings of the registry and regional prevalence of MS. Method In 2015, a national MS registry was launched in KSA to register all MS patient with confirmed diagnosis according to the 2010 McDonald Criteria. The registry aimed to identify and recruit all healthcare facilities treating MS patients in the Kingdom, and collect data such as demographics, clinical characteristics (disease onset, diagnosis, presentation of symptoms at onset, disease course, relapse rate, and disability measures), family history, and treatments. All the included sites have obtained IRB/EC approvals for participating in the registry. Currently, the registry includes 20 hospitals from different regions across the Kingdom. The Projected prevalence was calculated based on the assumption that the number of diagnosed MS cases in participating hospitals (in each region) is similar to the number of cases in remaining nonparticipant hospitals in the same region. Results As of September 2018, the registry has included 20 hospitals from the different regions across the Kingdom and has collected comprehensive data on 2516 patients from those hospitals, with median age 32 (Range: 11-63) and 66.5% being females. The reported prevalence of MS for those hospitals was estimated to be 7.70/100,000 population and 11.80/100,000 Saudi nationals. Based on the assumption made earlier, we projected the prevalence for each region and for the country as a whole. The overall prevalence of MS at the country level was reported to be 40.40/100,000 total population and 61.95/100,000 Saudi nationals. Around 3 out of every 4 patients (77.5%) were 40 years of age or younger. Female to male ratio was 2:1. The prevalence was higher among females, young and educated individuals across all five regions of Saudi Arabia. Conclusion The prevalence of MS has significantly increased in Saudi Arabia but is still much lower than that in the western and other neighboring countries like Kuwait, Qatar, and the UAE. However, compared to the past rates, Saudi Arabia's projected prevalence of MS through this national study is 40.40/100,000 population, putting the Kingdom above the low risk zone as per Kurtzke classification. The projected prevalence was estimated to be much higher among Saudi nationals (61.95/100,000 Saudi-nationals). The prevalence was higher among female, younger and educated individuals. Further studies are needed to assess the risk factors associated with increased prevalence in Saudi Arabia. Keywords: Prevalence, Multiple sclerosis, Registry, Saudi Arabia Background In 2015, the first nationwide, multicenter Multiple Sclerosis (MS) registry was initiated in the Kingdom of Saudi Arabia (KSA) mainly with an objective to describe current epidemiology, disease patterns, and clinical characteristics of MS in Saudi Arabia. This article aimed to report initial findings of the registry and regional prevalence of MS. Method In 2015, a national MS registry was launched in KSA to register all MS patient with confirmed diagnosis according to the 2010 McDonald Criteria. The registry aimed to identify and recruit all healthcare facilities treating MS patients in the Kingdom, and collect data such as demographics, clinical characteristics (disease onset, diagnosis, presentation of symptoms at onset, disease course, relapse rate, and disability measures), family history, and treatments. All the included sites have obtained IRB/EC approvals for participating in the registry. Currently, the registry includes 20 hospitals from different regions across the Kingdom. The Projected prevalence was calculated based on the assumption that the number of diagnosed MS cases in participating hospitals (in each region) is similar to the number of cases in remaining nonparticipant hospitals in the same region. Results As of September 2018, the registry has included 20 hospitals from the different regions across the Kingdom and has collected comprehensive data on 2516 patients from those hospitals, with median age 32 (Range: 11–63) and 66.5% being females. The reported prevalence of MS for those hospitals was estimated to be 7.70/100,000 population and 11.80/100,000 Saudi nationals. Based on the assumption made earlier, we projected the prevalence for each region and for the country as a whole. The overall prevalence of MS at the country level was reported to be 40.40/100,000 total population and 61.95/100,000 Saudi nationals. Around 3 out of every 4 patients (77.5%) were 40 years of age or younger. Female to male ratio was 2:1. The prevalence was higher among females, young and educated individuals across all five regions of Saudi Arabia. Conclusion The prevalence of MS has significantly increased in Saudi Arabia but is still much lower than that in the western and other neighboring countries like Kuwait, Qatar, and the UAE. However, compared to the past rates, Saudi Arabia’s projected prevalence of MS through this national study is 40.40/100,000 population, putting the Kingdom above the low risk zone as per Kurtzke classification. The projected prevalence was estimated to be much higher among Saudi nationals (61.95/100,000 Saudi-nationals). The prevalence was higher among female, younger and educated individuals. Further studies are needed to assess the risk factors associated with increased prevalence in Saudi Arabia. Abstract Background In 2015, the first nationwide, multicenter Multiple Sclerosis (MS) registry was initiated in the Kingdom of Saudi Arabia (KSA) mainly with an objective to describe current epidemiology, disease patterns, and clinical characteristics of MS in Saudi Arabia. This article aimed to report initial findings of the registry and regional prevalence of MS. Method In 2015, a national MS registry was launched in KSA to register all MS patient with confirmed diagnosis according to the 2010 McDonald Criteria. The registry aimed to identify and recruit all healthcare facilities treating MS patients in the Kingdom, and collect data such as demographics, clinical characteristics (disease onset, diagnosis, presentation of symptoms at onset, disease course, relapse rate, and disability measures), family history, and treatments. All the included sites have obtained IRB/EC approvals for participating in the registry. Currently, the registry includes 20 hospitals from different regions across the Kingdom. The Projected prevalence was calculated based on the assumption that the number of diagnosed MS cases in participating hospitals (in each region) is similar to the number of cases in remaining nonparticipant hospitals in the same region. Results As of September 2018, the registry has included 20 hospitals from the different regions across the Kingdom and has collected comprehensive data on 2516 patients from those hospitals, with median age 32 (Range: 11–63) and 66.5% being females. The reported prevalence of MS for those hospitals was estimated to be 7.70/100,000 population and 11.80/100,000 Saudi nationals. Based on the assumption made earlier, we projected the prevalence for each region and for the country as a whole. The overall prevalence of MS at the country level was reported to be 40.40/100,000 total population and 61.95/100,000 Saudi nationals. Around 3 out of every 4 patients (77.5%) were 40 years of age or younger. Female to male ratio was 2:1. The prevalence was higher among females, young and educated individuals across all five regions of Saudi Arabia. Conclusion The prevalence of MS has significantly increased in Saudi Arabia but is still much lower than that in the western and other neighboring countries like Kuwait, Qatar, and the UAE. However, compared to the past rates, Saudi Arabia’s projected prevalence of MS through this national study is 40.40/100,000 population, putting the Kingdom above the low risk zone as per Kurtzke classification. The projected prevalence was estimated to be much higher among Saudi nationals (61.95/100,000 Saudi-nationals). The prevalence was higher among female, younger and educated individuals. Further studies are needed to assess the risk factors associated with increased prevalence in Saudi Arabia. In 2015, the first nationwide, multicenter Multiple Sclerosis (MS) registry was initiated in the Kingdom of Saudi Arabia (KSA) mainly with an objective to describe current epidemiology, disease patterns, and clinical characteristics of MS in Saudi Arabia. This article aimed to report initial findings of the registry and regional prevalence of MS.BACKGROUNDIn 2015, the first nationwide, multicenter Multiple Sclerosis (MS) registry was initiated in the Kingdom of Saudi Arabia (KSA) mainly with an objective to describe current epidemiology, disease patterns, and clinical characteristics of MS in Saudi Arabia. This article aimed to report initial findings of the registry and regional prevalence of MS.In 2015, a national MS registry was launched in KSA to register all MS patient with confirmed diagnosis according to the 2010 McDonald Criteria. The registry aimed to identify and recruit all healthcare facilities treating MS patients in the Kingdom, and collect data such as demographics, clinical characteristics (disease onset, diagnosis, presentation of symptoms at onset, disease course, relapse rate, and disability measures), family history, and treatments. All the included sites have obtained IRB/EC approvals for participating in the registry. Currently, the registry includes 20 hospitals from different regions across the Kingdom. The Projected prevalence was calculated based on the assumption that the number of diagnosed MS cases in participating hospitals (in each region) is similar to the number of cases in remaining nonparticipant hospitals in the same region.METHODIn 2015, a national MS registry was launched in KSA to register all MS patient with confirmed diagnosis according to the 2010 McDonald Criteria. The registry aimed to identify and recruit all healthcare facilities treating MS patients in the Kingdom, and collect data such as demographics, clinical characteristics (disease onset, diagnosis, presentation of symptoms at onset, disease course, relapse rate, and disability measures), family history, and treatments. All the included sites have obtained IRB/EC approvals for participating in the registry. Currently, the registry includes 20 hospitals from different regions across the Kingdom. The Projected prevalence was calculated based on the assumption that the number of diagnosed MS cases in participating hospitals (in each region) is similar to the number of cases in remaining nonparticipant hospitals in the same region.As of September 2018, the registry has included 20 hospitals from the different regions across the Kingdom and has collected comprehensive data on 2516 patients from those hospitals, with median age 32 (Range: 11-63) and 66.5% being females. The reported prevalence of MS for those hospitals was estimated to be 7.70/100,000 population and 11.80/100,000 Saudi nationals. Based on the assumption made earlier, we projected the prevalence for each region and for the country as a whole. The overall prevalence of MS at the country level was reported to be 40.40/100,000 total population and 61.95/100,000 Saudi nationals. Around 3 out of every 4 patients (77.5%) were 40 years of age or younger. Female to male ratio was 2:1. The prevalence was higher among females, young and educated individuals across all five regions of Saudi Arabia.RESULTSAs of September 2018, the registry has included 20 hospitals from the different regions across the Kingdom and has collected comprehensive data on 2516 patients from those hospitals, with median age 32 (Range: 11-63) and 66.5% being females. The reported prevalence of MS for those hospitals was estimated to be 7.70/100,000 population and 11.80/100,000 Saudi nationals. Based on the assumption made earlier, we projected the prevalence for each region and for the country as a whole. The overall prevalence of MS at the country level was reported to be 40.40/100,000 total population and 61.95/100,000 Saudi nationals. Around 3 out of every 4 patients (77.5%) were 40 years of age or younger. Female to male ratio was 2:1. The prevalence was higher among females, young and educated individuals across all five regions of Saudi Arabia.The prevalence of MS has significantly increased in Saudi Arabia but is still much lower than that in the western and other neighboring countries like Kuwait, Qatar, and the UAE. However, compared to the past rates, Saudi Arabia's projected prevalence of MS through this national study is 40.40/100,000 population, putting the Kingdom above the low risk zone as per Kurtzke classification. The projected prevalence was estimated to be much higher among Saudi nationals (61.95/100,000 Saudi-nationals). The prevalence was higher among female, younger and educated individuals. Further studies are needed to assess the risk factors associated with increased prevalence in Saudi Arabia.CONCLUSIONThe prevalence of MS has significantly increased in Saudi Arabia but is still much lower than that in the western and other neighboring countries like Kuwait, Qatar, and the UAE. However, compared to the past rates, Saudi Arabia's projected prevalence of MS through this national study is 40.40/100,000 population, putting the Kingdom above the low risk zone as per Kurtzke classification. The projected prevalence was estimated to be much higher among Saudi nationals (61.95/100,000 Saudi-nationals). The prevalence was higher among female, younger and educated individuals. Further studies are needed to assess the risk factors associated with increased prevalence in Saudi Arabia. In 2015, the first nationwide, multicenter Multiple Sclerosis (MS) registry was initiated in the Kingdom of Saudi Arabia (KSA) mainly with an objective to describe current epidemiology, disease patterns, and clinical characteristics of MS in Saudi Arabia. This article aimed to report initial findings of the registry and regional prevalence of MS. In 2015, a national MS registry was launched in KSA to register all MS patient with confirmed diagnosis according to the 2010 McDonald Criteria. The registry aimed to identify and recruit all healthcare facilities treating MS patients in the Kingdom, and collect data such as demographics, clinical characteristics (disease onset, diagnosis, presentation of symptoms at onset, disease course, relapse rate, and disability measures), family history, and treatments. All the included sites have obtained IRB/EC approvals for participating in the registry. Currently, the registry includes 20 hospitals from different regions across the Kingdom. The Projected prevalence was calculated based on the assumption that the number of diagnosed MS cases in participating hospitals (in each region) is similar to the number of cases in remaining nonparticipant hospitals in the same region. As of September 2018, the registry has included 20 hospitals from the different regions across the Kingdom and has collected comprehensive data on 2516 patients from those hospitals, with median age 32 (Range: 11-63) and 66.5% being females. The reported prevalence of MS for those hospitals was estimated to be 7.70/100,000 population and 11.80/100,000 Saudi nationals. Based on the assumption made earlier, we projected the prevalence for each region and for the country as a whole. The overall prevalence of MS at the country level was reported to be 40.40/100,000 total population and 61.95/100,000 Saudi nationals. Around 3 out of every 4 patients (77.5%) were 40 years of age or younger. Female to male ratio was 2:1. The prevalence was higher among females, young and educated individuals across all five regions of Saudi Arabia. The prevalence of MS has significantly increased in Saudi Arabia but is still much lower than that in the western and other neighboring countries like Kuwait, Qatar, and the UAE. However, compared to the past rates, Saudi Arabia's projected prevalence of MS through this national study is 40.40/100,000 population, putting the Kingdom above the low risk zone as per Kurtzke classification. The projected prevalence was estimated to be much higher among Saudi nationals (61.95/100,000 Saudi-nationals). The prevalence was higher among female, younger and educated individuals. Further studies are needed to assess the risk factors associated with increased prevalence in Saudi Arabia. In 2015, the first nationwide, multicenter Multiple Sclerosis (MS) registry was initiated in the Kingdom of Saudi Arabia (KSA) mainly with an objective to describe current epidemiology, disease patterns, and clinical characteristics of MS in Saudi Arabia. This article aimed to report initial findings of the registry and regional prevalence of MS. In 2015, a national MS registry was launched in KSA to register all MS patient with confirmed diagnosis according to the 2010 McDonald Criteria. The registry aimed to identify and recruit all healthcare facilities treating MS patients in the Kingdom, and collect data such as demographics, clinical characteristics (disease onset, diagnosis, presentation of symptoms at onset, disease course, relapse rate, and disability measures), family history, and treatments. All the included sites have obtained IRB/EC approvals for participating in the registry. Currently, the registry includes 20 hospitals from different regions across the Kingdom. The Projected prevalence was calculated based on the assumption that the number of diagnosed MS cases in participating hospitals (in each region) is similar to the number of cases in remaining nonparticipant hospitals in the same region. As of September 2018, the registry has included 20 hospitals from the different regions across the Kingdom and has collected comprehensive data on 2516 patients from those hospitals, with median age 32 (Range: 11-63) and 66.5% being females. The reported prevalence of MS for those hospitals was estimated to be 7.70/100,000 population and 11.80/100,000 Saudi nationals. Based on the assumption made earlier, we projected the prevalence for each region and for the country as a whole. The overall prevalence of MS at the country level was reported to be 40.40/100,000 total population and 61.95/100,000 Saudi nationals. Around 3 out of every 4 patients (77.5%) were 40 years of age or younger. Female to male ratio was 2:1. The prevalence was higher among females, young and educated individuals across all five regions of Saudi Arabia. The prevalence of MS has significantly increased in Saudi Arabia but is still much lower than that in the western and other neighboring countries like Kuwait, Qatar, and the UAE. However, compared to the past rates, Saudi Arabia's projected prevalence of MS through this national study is 40.40/100,000 population, putting the Kingdom above the low risk zone as per Kurtzke classification. The projected prevalence was estimated to be much higher among Saudi nationals (61.95/100,000 Saudi-nationals). The prevalence was higher among female, younger and educated individuals. Further studies are needed to assess the risk factors associated with increased prevalence in Saudi Arabia. |
| ArticleNumber | 49 |
| Audience | Academic |
| Author | Saeedi, J. Almudaiheem, H. El-Metwally, A. Ishak, S. Karim, A. Bunyan, R. Al Otaibi, H. Mohamednour, E. Algahtani, H. Alrajeh, S. Almalki, A. Almubarak, A. Al Malik, Y. Alzahrani, N. Cupler, E. Nahrir, S. Al Mejally, M. Al Towaijri, G. Qureshi, S. Althubaiti, I. Alhazzani, A. AlJumah, Mohammed Kalakatawi, M. Alawi, S. Al-Jedai, A. |
| Author_xml | – sequence: 1 givenname: Mohammed surname: AlJumah fullname: AlJumah, Mohammed email: jumahm@gmail.com organization: King Fahd Medical City (KFMC), MOH – sequence: 2 givenname: R. surname: Bunyan fullname: Bunyan, R. organization: King Fahd Specialist Hospital (KFSH)-Dammam – sequence: 3 givenname: H. surname: Al Otaibi fullname: Al Otaibi, H. organization: King Fahd General Hospital-Jeddah – sequence: 4 givenname: G. surname: Al Towaijri fullname: Al Towaijri, G. organization: King Fahd Medical City (KFMC), MOH – sequence: 5 givenname: A. surname: Karim fullname: Karim, A. organization: King Fahd General Hospital-Al-Madinah – sequence: 6 givenname: Y. surname: Al Malik fullname: Al Malik, Y. organization: King Abdulaziz Medical City (National Guard Health Affairs)-Riyadh, King Saud bin Abdulaziz University For Health Sciences – sequence: 7 givenname: M. surname: Kalakatawi fullname: Kalakatawi, M. organization: Nour Specialized Hospital – sequence: 8 givenname: S. surname: Alrajeh fullname: Alrajeh, S. organization: Dr. Sulaiman Al Habib Hospital-Olaya Branch – sequence: 9 givenname: M. surname: Al Mejally fullname: Al Mejally, M. organization: Heraa General Hospital – sequence: 10 givenname: H. surname: Algahtani fullname: Algahtani, H. organization: King Abdul-Aziz Medical City (National Guard Health Affairs) – sequence: 11 givenname: A. surname: Almubarak fullname: Almubarak, A. organization: Qatif Central Hospital – sequence: 12 givenname: E. surname: Cupler fullname: Cupler, E. organization: King Faisal Specialist Hospital & Research Center – sequence: 13 givenname: S. surname: Alawi fullname: Alawi, S. organization: Prince Sultan Military Medical City – sequence: 14 givenname: S. surname: Qureshi fullname: Qureshi, S. organization: Johns Hopkins Aramco Healthcare Company (JHAH) – sequence: 15 givenname: S. surname: Nahrir fullname: Nahrir, S. organization: King Saud Medical City – sequence: 16 givenname: A. surname: Almalki fullname: Almalki, A. organization: King Abdul-Aziz Hospital and Oncology Center – sequence: 17 givenname: A. surname: Alhazzani fullname: Alhazzani, A. organization: King Saud University – sequence: 18 givenname: I. surname: Althubaiti fullname: Althubaiti, I. organization: King Fahad Military Medical Complex – sequence: 19 givenname: N. surname: Alzahrani fullname: Alzahrani, N. organization: King Fahd General Hospital – sequence: 20 givenname: E. surname: Mohamednour fullname: Mohamednour, E. organization: King Fahad Specialist Hospital – sequence: 21 givenname: J. surname: Saeedi fullname: Saeedi, J. organization: King Abdullah Bin Abdulaziz University Hospital – sequence: 22 givenname: S. surname: Ishak fullname: Ishak, S. organization: Itkan Health Consulting – sequence: 23 givenname: H. surname: Almudaiheem fullname: Almudaiheem, H. organization: Ministry of Health, Deputyship of Therapeutic Affairs – sequence: 24 givenname: A. surname: El-Metwally fullname: El-Metwally, A. organization: King Saud bin Abdulaziz University For Health Sciences – sequence: 25 givenname: A. surname: Al-Jedai fullname: Al-Jedai, A. organization: Ministry of Health, Deputyship of Therapeutic Affairs |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32035478$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kkuLFDEUhQsZcR76A9xIgZtZWGNuUpXHRmgGdQYaBB_rkErdtGmqK21S1TD_3pQ9rx5Uski4-c5JcnNOi6MhDFgUr4FcAEj-PgGVklWEkgo4VRV7VpxALaCiTIijR-vj4jSlNSEgZA0vimNGCWtqIU-K5Vef_LAqtxF3psfBYhlcuZn60W97LJPtMYbkU-mH8puZOl8uomm9eVeassNko9-OfpfBcepuXhbPnekTvrqdz4ofnz5-v7yqll8-X18ulpXlhI2VkVY44LITggFS4CAoik5JUAxcI6VCRSSIum3RWUN5LnAOyjlQWCOys-J679sFs9bb6Dcm3uhgvP5TCHGlTRx9vrtulc0tci1YFLWkQja1Yg0wbpqaO2Ky14e913ZqN9hZHMZo-gPTw53B_9SrsNOCEMEblQ3Obw1i-DVhGvXGJ4t9bwYMU9KUNYwQ1VDI6Nsn6DpMccitmikhVE0Ze6BW-UO0H1zI59rZVC848Mw0imbq4i9UHh1uvM05cT7XDwRvHj_0_oV3WcgA7AGbfzxFdPcIED3nTe_zpnPe9Jw3Pd9VPNFYP5rRh7lXvv-vku6VKZ8yrDA-9OLfot9VQ-Xy |
| CitedBy_id | crossref_primary_10_1097_MD_0000000000035889 crossref_primary_10_1186_s12883_022_02632_2 crossref_primary_10_3389_fneur_2023_1194212 crossref_primary_10_7759_cureus_81735 crossref_primary_10_4103_aam_aam_49_24 crossref_primary_10_1016_j_msard_2021_102875 crossref_primary_10_1016_j_msard_2023_104734 crossref_primary_10_1186_s12883_021_02170_3 crossref_primary_10_1016_j_msard_2024_105629 crossref_primary_10_1089_tmj_2023_0151 crossref_primary_10_3389_fneur_2024_1491193 crossref_primary_10_1186_s13568_023_01553_8 crossref_primary_10_3389_fimmu_2022_844461 crossref_primary_10_1097_MD_0000000000038369 crossref_primary_10_3390_brainsci13071009 crossref_primary_10_1055_s_0041_1734009 crossref_primary_10_7759_cureus_24181 crossref_primary_10_1177_2055217320960499 crossref_primary_10_1016_j_msard_2022_103671 crossref_primary_10_1080_14737167_2024_2364832 crossref_primary_10_1108_IJHRH_01_2021_0007 crossref_primary_10_1080_09638288_2024_2350618 crossref_primary_10_3390_ijerph182413261 crossref_primary_10_3390_ctn7020010 crossref_primary_10_1080_01616412_2021_1952511 crossref_primary_10_4103_ATMR_ATMR_101_24 crossref_primary_10_1177_20552173221077185 crossref_primary_10_1186_s40001_023_01079_6 crossref_primary_10_1007_s40120_022_00401_4 crossref_primary_10_1371_journal_pone_0263606 crossref_primary_10_7759_cureus_41650 crossref_primary_10_1186_s12883_023_03184_9 crossref_primary_10_1016_j_msard_2023_105153 crossref_primary_10_1080_09638288_2021_1919929 crossref_primary_10_3389_fpsyt_2023_1195101 crossref_primary_10_3389_fneur_2024_1395822 crossref_primary_10_7759_cureus_42061 crossref_primary_10_1016_j_heliyon_2024_e39589 crossref_primary_10_57197_JDR_2025_0010 crossref_primary_10_3897_folmed_67_e143137 crossref_primary_10_3390_clinpract14060217 crossref_primary_10_7759_cureus_54852 crossref_primary_10_1007_s40120_025_00767_1 crossref_primary_10_1016_j_msard_2023_104838 crossref_primary_10_7759_cureus_28689 crossref_primary_10_7224_1537_2073_2020_125 crossref_primary_10_1186_s12913_023_09462_z crossref_primary_10_3390_medicina61040730 crossref_primary_10_3389_fnmol_2024_1503396 crossref_primary_10_1186_s12913_024_11800_8 crossref_primary_10_7759_cureus_25851 crossref_primary_10_4103_jfmpc_jfmpc_1838_24 crossref_primary_10_2147_PPA_S414884 crossref_primary_10_7759_cureus_13619 crossref_primary_10_1016_j_msard_2021_103034 crossref_primary_10_1016_j_msard_2021_103276 crossref_primary_10_4103_jfcm_jfcm_263_24 crossref_primary_10_1016_j_msard_2023_105014 crossref_primary_10_1177_17449871241290435 crossref_primary_10_3390_ctn7010005 crossref_primary_10_1016_j_msard_2021_103119 crossref_primary_10_1155_2021_6667006 crossref_primary_10_1177_1756286420954119 crossref_primary_10_46413_boneyusbad_1526406 crossref_primary_10_1155_2021_4226141 crossref_primary_10_7759_cureus_20792 crossref_primary_10_3390_ijerph20054261 crossref_primary_10_7759_cureus_49353 crossref_primary_10_3389_fresc_2025_1433276 crossref_primary_10_1016_j_pharma_2023_03_005 |
| Cites_doi | 10.1159/000431042 10.1111/ene.12045 10.1007/s00415-015-7842-0 10.1016/S1474-4422(11)70235-6 10.1016/j.msard.2019.04.033 10.1177/1352458512459291 10.1212/WNL.0000000000000768 10.1016/S1474-4422(10)70064-8 10.1016/j.msard.2016.07.005 10.1007/s00415-008-6001-2 10.1212/WNL.90.15_supplement.P2.390 10.2147/NDT.S140869 10.1007/s00415-013-6876-4 10.3389/fneur.2018.00201 10.1038/labinvest.3780235 10.1055/s-0036-1579693 10.1016/S1474-4422(18)30443-5 10.1186/s12883-018-1090-8 10.1371/journal.pone.0167556 |
| ContentType | Journal Article |
| Copyright | The Author(s). 2020 COPYRIGHT 2020 BioMed Central Ltd. 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s). 2020 – notice: COPYRIGHT 2020 BioMed Central Ltd. – notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION NPM 3V. 7TK 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12883-020-1629-3 |
| DatabaseName | Springer Nature OA Free Journals CrossRef PubMed ProQuest Central (Corporate) Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals (DOAJ) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Statistics |
| EISSN | 1471-2377 |
| EndPage | 7 |
| ExternalDocumentID | oai_doaj_org_article_b9c883fb1ce74827854935136a546f0a PMC7007659 A616423592 32035478 10_1186_s12883_020_1629_3 |
| Genre | Journal Article |
| GeographicLocations | Saudi Arabia |
| GeographicLocations_xml | – name: Saudi Arabia |
| GrantInformation_xml | – fundername: King Abdulaziz City for Science and Technology (KACST) grantid: grant # AT-34-438 – fundername: ; grantid: grant # AT-34-438 |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABIVO ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IGS IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX AFFHD CITATION -A0 3V. ACRMQ ADINQ ALIPV C24 NPM 7TK 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c603t-a8c7f168d7731e216172e7d981931f5889e908174bbefca2689e6619ff19e4ee3 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 88 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000512729900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1471-2377 |
| IngestDate | Fri Oct 03 12:50:51 EDT 2025 Tue Nov 04 02:03:07 EST 2025 Fri Sep 05 10:21:40 EDT 2025 Thu Oct 09 21:52:15 EDT 2025 Tue Nov 11 10:44:18 EST 2025 Tue Nov 04 18:07:38 EST 2025 Thu Jan 02 23:00:10 EST 2025 Tue Nov 18 22:35:12 EST 2025 Sat Nov 29 01:39:56 EST 2025 Sat Sep 06 07:35:57 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Saudi Arabia Multiple sclerosis Prevalence Registry |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c603t-a8c7f168d7731e216172e7d981931f5889e908174bbefca2689e6619ff19e4ee3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://link.springer.com/10.1186/s12883-020-1629-3 |
| PMID | 32035478 |
| PQID | 2357794233 |
| PQPubID | 44772 |
| PageCount | 7 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_b9c883fb1ce74827854935136a546f0a pubmedcentral_primary_oai_pubmedcentral_nih_gov_7007659 proquest_miscellaneous_2353009521 proquest_journals_2357794233 gale_infotracmisc_A616423592 gale_infotracacademiconefile_A616423592 pubmed_primary_32035478 crossref_primary_10_1186_s12883_020_1629_3 crossref_citationtrail_10_1186_s12883_020_1629_3 springer_journals_10_1186_s12883_020_1629_3 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-02-08 |
| PublicationDateYYYYMMDD | 2020-02-08 |
| PublicationDate_xml | – month: 02 year: 2020 text: 2020-02-08 day: 08 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC neurology |
| PublicationTitleAbbrev | BMC Neurol |
| PublicationTitleAlternate | BMC Neurol |
| PublicationYear | 2020 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | MT Wallin (1629_CR4) 2019; 18 P Browne (1629_CR1) 2014; 83 S Paul (1629_CR10) 2019; 17 D Deleu (1629_CR16) 2013; 19 S Bohlega (1629_CR11) 2013; 260 P Heydarpour (1629_CR18) 2015; 44 A Gajofatto (1629_CR20) 2013; 20 T Korn (1629_CR6) 2008; 255 D Pivot (1629_CR21) 2016; 11 DM Wingerchuk (1629_CR7) 2001; 81 A Ascherio (1629_CR9) 2016; 36 E Kingwell (1629_CR22) 2015; 262 1629_CR13 Saudi General Authority for Statistics (1629_CR14) 2016 TK Karikari (1629_CR2) 2018; 9 O Al Wutayd (1629_CR12) 2018; 18 N Schiess (1629_CR17) 2016; 9 N Koch-Henriksen (1629_CR8) 2010; 9 R Alroughani (1629_CR15) 2019; 32 SM Hamdy (1629_CR23) 2017; 13 1629_CR5 E Carreon-Guarnizo (1629_CR19) 2016; 62 D Mohammadi (1629_CR3) 2011; 10 |
| References_xml | – volume: 44 start-page: 232 issue: 4 year: 2015 ident: 1629_CR18 publication-title: Neuroepidemiology doi: 10.1159/000431042 – volume: 20 start-page: 697 issue: 4 year: 2013 ident: 1629_CR20 publication-title: Eur J Neurol doi: 10.1111/ene.12045 – volume: 262 start-page: 2352 issue: 10 year: 2015 ident: 1629_CR22 publication-title: J Neurol doi: 10.1007/s00415-015-7842-0 – volume: 10 start-page: 953 issue: 11 year: 2011 ident: 1629_CR3 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(11)70235-6 – volume: 17 start-page: 1 year: 2019 ident: 1629_CR10 publication-title: Neuropsychol Rev – ident: 1629_CR5 – volume: 32 start-page: 74 year: 2019 ident: 1629_CR15 publication-title: Mult Scler Relat Disord doi: 10.1016/j.msard.2019.04.033 – volume: 19 start-page: 816 issue: 6 year: 2013 ident: 1629_CR16 publication-title: Mult Scler J doi: 10.1177/1352458512459291 – volume: 83 start-page: 1022 issue: 11 year: 2014 ident: 1629_CR1 publication-title: Neurology doi: 10.1212/WNL.0000000000000768 – volume: 9 start-page: 520 issue: 5 year: 2010 ident: 1629_CR8 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(10)70064-8 – volume: 9 start-page: 73 year: 2016 ident: 1629_CR17 publication-title: Mult Scler Relat Disord doi: 10.1016/j.msard.2016.07.005 – volume: 255 start-page: 2 issue: 6 year: 2008 ident: 1629_CR6 publication-title: J Neurol doi: 10.1007/s00415-008-6001-2 – ident: 1629_CR13 doi: 10.1212/WNL.90.15_supplement.P2.390 – volume: 13 start-page: 1895 year: 2017 ident: 1629_CR23 publication-title: Neuropsychiatr Dis Treat doi: 10.2147/NDT.S140869 – volume: 260 start-page: 2959 issue: 12 year: 2013 ident: 1629_CR11 publication-title: J Neurol doi: 10.1007/s00415-013-6876-4 – volume: 9 start-page: 201 year: 2018 ident: 1629_CR2 publication-title: Front Neurol doi: 10.3389/fneur.2018.00201 – volume: 81 start-page: 263 issue: 3 year: 2001 ident: 1629_CR7 publication-title: Lab Investig doi: 10.1038/labinvest.3780235 – volume: 36 start-page: 103 issue: 02 year: 2016 ident: 1629_CR9 publication-title: Semin Neurol doi: 10.1055/s-0036-1579693 – volume: 62 start-page: 396 issue: 9 year: 2016 ident: 1629_CR19 publication-title: Rev Neurol – volume: 18 start-page: 269 year: 2019 ident: 1629_CR4 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(18)30443-5 – volume: 18 start-page: 86 issue: 1 year: 2018 ident: 1629_CR12 publication-title: BMC Neurol doi: 10.1186/s12883-018-1090-8 – volume: 11 start-page: 12 year: 2016 ident: 1629_CR21 publication-title: PLoS One doi: 10.1371/journal.pone.0167556 – volume-title: Annual Report 2016 year: 2016 ident: 1629_CR14 |
| SSID | ssj0017841 |
| Score | 2.5146627 |
| Snippet | Background
In 2015, the first nationwide, multicenter Multiple Sclerosis (MS) registry was initiated in the Kingdom of Saudi Arabia (KSA) mainly with an... In 2015, the first nationwide, multicenter Multiple Sclerosis (MS) registry was initiated in the Kingdom of Saudi Arabia (KSA) mainly with an objective to... Background In 2015, the first nationwide, multicenter Multiple Sclerosis (MS) registry was initiated in the Kingdom of Saudi Arabia (KSA) mainly with an... Abstract Background In 2015, the first nationwide, multicenter Multiple Sclerosis (MS) registry was initiated in the Kingdom of Saudi Arabia (KSA) mainly with... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 49 |
| SubjectTerms | Age Demographic aspects Demography Demyelinating diseases Diagnosis Disabilities Diseases Epidemiology Forecasts and trends Hospitals Medical research Medicine Medicine & Public Health Multiple sclerosis Neurochemistry Neurological research Neurology Neurosurgery Patients Population Prevalence Quality of life Registry Research Article Risk factors Saudi Arabia Statistics Variance analysis Vitamin deficiency |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Ni9UwEA-yiHgRv62uEkEQ1LJN0ubjuIqLh3URv9hbSJuELUjf8vre_v3OpOlzu6JevCaTMpnOZGY6018IeSF0K53TvvTg-8q6Vr40XvAyVrGFkB8C_ATX9P1YnZzo01Pz6dJVX9gTNsEDT4I7aE2ntYgt64JCyEoNCY1omJCuqWWsUmgEUc-cTOX6AVbTcg2TaXkwMrxUt8RUiUluSrHwQgms__cj-ZJPutoveaVomnzR0W1yKweR9HBi_g65Foa75MbHXCa_R44_9_gJgJ6vEcwbbZeuIp17B-kIi4CtfqT9QL-4re_hUa7t3RvqqA_5ILkAQsSevU--Hb3_-u5Dma9NKDtZiU3pdKcik9orJVjgmMDwoLwB3y9YbLQ2wUAgoOq2DbFzXMIAeGkTIzOhDkE8IHvDagiPCPWtaTWmJKZytfAId-cZQtq7xkGi5wtSzWK0XcYUx6stftiUW2hpJ8lbkLxFyVtRkFe7JecToMbfiN_iu9kRIhZ2GgANsVlD7L80pCAv8c1atFhgrnP5xwPYImJf2UMJKSMXjeEF2V9QgqV1y-lZN2y29NEiXBCcaVwAs89307gSu9eGsNomGoGxLGcFeTip0m5LglcCMdUKohZKttjzcmbozxIOuMIyamMK8npWx19s_VGkj_-HSJ-QmxyNCbvX9T7Z26y34Sm53l1s-nH9LJniT5WtMaw priority: 102 providerName: Directory of Open Access Journals – databaseName: Publicly Available Content Database dbid: PIMPY link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9QwDLfghtBe-P4oDFQkJCSguqbpR_KEBmICaZtOfGk8RWmTQKWpPa53-_ux2_RGh9gTr4lTxbXj2LX7M8BzLspca2Eig3dflKaFiaThSeRiV6LLjw5-D9f07bA4PhYnJ3Lhf4_ufFnlaBN7Qz2gPVPdNhrhuWkr-mI-J5AW1KSE8zfLXxH1kKJcq2-ocRV2CHhLzGBn8fFo8X2bVaAcm89sMpHPO0atdiMKoFieyIhP7qYewv9vQ_3HTXWxivJCKrW_oQ5u_l_ebsEN76mG-4Nq3YYrtrkD1498Lv4uHH6q6TtDuFwRYjgZiLB14VigGHa4CLmsu7Buws96Y2p8lC5r_TrUobHeWp0hIQHc3oOvB--_vPsQ-d4MUZXHfB1pURWO5cIUBWc2oSgpsYWR6GBw5jIhpJXobRRpWVpX6STHAXQFpHNM2tRafh9mTdvYhxCaUpaC4h4Z65QbwtQzjHDzdaYxmjQBxKNUVOWBy6l_xqnqAxiRq0GQCgWpSJCKB_Byu2Q5oHZcRvyWRL0lJMDtfqBd_VD-_KpSVrjKlayyBSGnCoyrecZ4rrM0d7EO4AUpiiKzgJurtP-7AVkkgC21n2NcipKVSQB7E0o8ztV0etQR5c1Jp85VIoBn22laSSVyjW03PQ0nhzlhATwYNHPLEk9iTsBtARQTnZ3wPJ1p6p892HhBudpMBvBq1O7zbf3zlT66nInHsJvQqaPid7EHs_VqY5_AtepsXXerp_7U_gZ8Qk2r priority: 102 providerName: ProQuest |
| Title | Rising prevalence of multiple sclerosis in Saudi Arabia, a descriptive study |
| URI | https://link.springer.com/article/10.1186/s12883-020-1629-3 https://www.ncbi.nlm.nih.gov/pubmed/32035478 https://www.proquest.com/docview/2357794233 https://www.proquest.com/docview/2353009521 https://pubmed.ncbi.nlm.nih.gov/PMC7007659 https://doaj.org/article/b9c883fb1ce74827854935136a546f0a |
| Volume | 20 |
| WOSCitedRecordID | wos000512729900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: Directory of Open Access Journals (DOAJ) customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: RSV dateStart: 20011201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ri9QwEB-8OxG_-H5Uz6WCIKjFNmmb5OOd3KFwtyx7eqyfQtqkWpDusd29v9-ZbFvt-QD9UthmpiSz8-ykvwC84LLIjZE2shj7ojQVNlKWs6iKqwJTfkzwPVzT-YmYTuVioWbdd9xtv9u9b0l6T-3NWuZv24QOxo2o3ElypiK-A3sY7SRZ4_zsfGgdUCOta1_-lm0UgDxO_6_e-KdwdHWr5JV-qQ9Dx7f_awF34FaXdYYHWzW5C9dccw9unHZ99ftwMq_pnUF4sSL0bzL2cFmF_WbDsEUmXEzdhnUTnpmNrfFRpqjNm9CE1nWe5xIJCaz2AXw6Pvr47n3UnbMQlXnM15GRpaiSXFoheOIYVTzMCYuiVTypMimVU5g5iLQoXFUaluMNDOuqqhLlUuf4Q9htlo17DKEtVCGphlGxSbklfDybEAa-yQxWhjaAuBe-LjsQcjoL45v2xYjM9VZKGqWkSUqaB_BqYLnYInD8jfiQ_tGBkMCz_Y3l6ovubFEXqkSuqkhKJwgFVWKNzLOE5yZL8yo2AbwkfdBk4ji50nRfKuASCSxLH-RYYzKeKRbA_ogSTbMcD_capTvX0GrCF0InyDhO9vkwTJy03a1xy42n4ZT8siSAR1sFHJbEWcwJhC0AMVLN0ZrHI0391QOHC-q7ZiqA172C_pjWH0X65J-on8JNRhpO-9rlPuyuVxv3DK6Xl-u6XU1gRyyEv8oJ7B0eTWfziX8Lgr9mH05nnyfelr8DJp88Qg |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgoAL70egQJBASEDU2E5i-4BQeVStul0hKGhvxokdiIR2l81uEX-K38hMNtmSInrrgWs8jmLnmxlPZvINwCOh8sxa5SKHvi9KEuki7QSPyrjM8ciPB_yGrunTQA6HajTS79bgV_cvDJVVdjaxMdRuUtA38k2iZUHscCFeTr9H1DWKsqtdC40lLPb8zx8YstUvdt_g-33M-fbbg9c7UdtVICqyWMwjqwpZskw5KQXznM733Eun0TUKVqZKaa_RT8okz31ZWJ7hBXRiuiyZ9on3Au97Bs6iHZdUQiZHqwCPUQ6vzZwylW3WjFr5RhSgsYzrSPR8X9Mi4G9H8IcnPF6leSxV23jA7cv_295dgUvtWTvcWirHVVjz42twfr-tJrgOg_cVfSkJpzPiPCcTF07KsCuxDGuchPtY1WE1Dj_YhavwVjav7PPQhs639vYQBYmi9wZ8PJW13IT18WTsb0Pocp0ritx0bBPhiBXQMWL-t6nFeNgFEHfv3RQt9Tp1APlmmhBMZWYJFYNQMQQVIwJ4upoyXfKOnCT8isC0EiTK8ObCZPbFtBbI5LrAWWXOCi-J-1WliRYpE5lNk6yMbQBPCIqGDBs-XGHb_zNwiUQRZrYyjKwRSZoHsNGTRINU9Ic7FJrWINbmCIIBPFwN00wq8hv7yaKREXTk5yyAW0vsr5YkeCyIei4A2dOK3pr7I-Pqa0OXLinbnOoAnnX6c_RY_9zSOycv4gFc2DnYH5jB7nDvLlzkpONUyq82YH0-W_h7cK44nFf17H5jIUL4fNpq9Ru2dZww |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Zb9QwEB5BQRUv3EegQJCQkKBREztx7MdyrEAsq4pC1TfLiW2IhLKrzW5_PzO5IOWQEK_xzMp25tyZfAPwlMtCGCNtZNH3RWma20hZziIf-wJDfgzwW7imk3m-WMjTU3XUzzlthm73oSTZfdNAKE315mBlfafiUhw0CQ3JjSj1SQRTEb8Il1KaGUTp-vHJWEagolpfyvwt28QZtZj9v1rmn1zT-bbJc7XT1iXNrv33Ya7D1T4aDQ878bkBF1x9E3Y_9PX2WzD_WNF_CeFqTajgZATCpQ-HJsSwQSY8WNWEVR0em62t8KdMUZn90ITW9RbpDAkJxPY2fJ69-fTqbdTPX4hKEfNNZGSZ-0RIm-c8cYwyIeZyqzCI4InPpFROYUSRp0XhfGmYwAfo7pX3iXKpc_wO7NTL2t2D0BaqkJTbqNik3BJunk0IG99kBjNGG0A8vAhd9uDkNCPjm26TFCl0d0sab0nTLWkewPORZdUhc_yN-CW93ZGQQLXbB8v1F93rqC5UiVy-SEqXEzqqxNyZZwkXJkuFj00Az0g2NKk-bq40_RcMeEQC0dKHAnNPxjPFAtibUKLKltPlQbp0bzIaTbhDaBwZx80-GZeJk9rgarfctjScgmKWBHC3E8bxSJzFnMDZAsgnYjo583Slrr62gOI51WMzFcCLQVh_bOuPV3r_n6gfw-7R65mev1u8fwBXGAk7tb7LPdjZrLfuIVwuzzZVs37UKvB36pNB-g |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rising+prevalence+of+multiple+sclerosis+in+Saudi+Arabia%2C+a+descriptive+study&rft.jtitle=BMC+neurology&rft.au=AlJumah%2C+Mohammed&rft.au=Bunyan%2C+R&rft.au=Al+Otaibi%2C+H&rft.au=Al+Towaijri%2C+G&rft.date=2020-02-08&rft.issn=1471-2377&rft.eissn=1471-2377&rft.volume=20&rft.issue=1&rft.spage=49&rft_id=info:doi/10.1186%2Fs12883-020-1629-3&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2377&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2377&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2377&client=summon |